In cancer, major histocompatibility complex (MHC) and co-stimulatory molecule expression increases following treatment with HDAC inhibitors allowing for activation of T cells and increased susceptibility to NK cell killing [99,100]. This evidence concerns the gene HDAC9 and cancer.